Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the study sample

From: Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial

  IFX + MTX MTX PL P value
Number of patients (n) 38 36 16 0.4440
Female 26 (68.4%) 28 (77.8%) 9 (56.3%) 0.2833
Age (years), mean ± SD 52.1 ± 14.1 52.9 ± 14.0 54.4 ± 11.2 0.9170
Symptom duration (weeks)a, mean ± SD 10.3 ± 2.3 9.4 ± 2.3 9.8 ± 1.8 0.0722
Rheumatoid factor positive 13 (34.2%) 13 (36.1%) 7 (43.8%) 0.7988
Patients who used steroids prior to the study 24 (63.2%) 22 (61.1%) 9 (56.3%) 0.8931
Anti-citrullinated protein antibody positive 18 (47.4%) 16 (44.4%) 7 (43.8%) 0.9563
Patients who meet the ACR/EULAR 2010 classification criteria for RA, 2010 [25] 26 (68%) 19 (53%) 12 (75%) 0.2135
Patients who meet the 1987 ARA classification criteria for RA [35] 22 (58%) 19 (53%) 9 (56%) 0.9049
Health Assessment Questionnaire (0–3) 0.9 ± 0.7 0.9 ± 0.6 0.7 ± 0.7 0.2903
Disease Activity Score 28 (DAS28; based on ESR) 5.0 ± 1.4 4.8 ± 1.3 4.7 ± 1.1 0.8464
Simplified Disease Activity Index (SDAI) 34.3 ± 23.8 31.1 ± 14.4 27.5 ± 20.0 0.4771
Clinical Disease Activity Index (CDAI) 25.1 ± 14.7 26.2 ± 13.9 23.5 ± 11.9 0.8951
Swollen joint count (0–28) 7.2 ± 5.7 6.50 ± 5.1 7.4 ± 4.6 0.7048
Tender joint count (0–28) 9.2 ± 7.3 10.3 ± 7.2 7.8 ± 5.6 0.5263
Visual analogue scale pain (mm) 44.0 ± 29.3 44.2 ± 24.3 44.6 ± 22.7 0.9595
Patient global assessment (mm) 48.6 ± 29.0 47.8 ± 24.7 39.6 ± 21.0 0.5274
Evaluator/physician global assessment (mm) 38.6 ± 18.3 46.3 ± 22.3 44.6 ± 20.7 0.3627
C-reactive protein (mg/dl) 1.71 ± 2.40 1.18 ± 1.88 0.98 ± 1.28 0.5567
Erythrocyte sedimentation rate (ESR; mm/h) 23.2 ± 20.3 20.3 ± 21.2 20.4 ± 12.6 0.8129
Total Sharp-van-der-Heide score 2.8 ± 5.4 3 ± 3.8 4.6 ± 8.6 0.4816
Erosion score 1.2 ± 1.8 1.6 ± 2.2 2.2 ± 4.2 0.6019
Joint space narrowing score 1.6 ± 3.8 1.4 ± 2.2 2.4 ± 4.4 0.5658
  1. Data are shown as mean ± standard deviation or n (%) as appropriate
  2. The parameters showed no significant differences between the three groups at baseline
  3. Tables with additional data on baseline characteristics as well as 1-year data for the patients who were in remission at 1 year are provided in Additional file 2 (Tables SC and SD)
  4. ACR American College of Rheumatology, ARA American Rheumatism Association, EULAR European League Against Rheumatism, IFX infliximab, MTX methotrexate, PL placebo, RA rheumatoid arthritis
  5. aSymptom duration refers to the first visit when the patients presented themselves at the centres. At the baseline visit, symptom duration of all patients was 12 weeks because baseline visits were scheduled at this time to ensure persistent arthritis for 12 weeks. Patients who had no residual arthritis at the baseline visit were excluded